Mabion (MAB.WA) Stock Price

Mabion Price

GPW·CLOSED
8.11
​
Market closed

Revenue has compounded at 16.8% per year over the past 15 years to 15.76 M PLN. Earnings per share have grown at 41.0% per year over the last 13 years. Mabion's net margin stands at -397.4%, down from 3.3% several years earlier. Analysts set a median price target of 10.20 PLN, implying 25.8% above the current price. Of 7 analysts, 0 rate the stock a buy — an overall Sell consensus.

Mabion stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mabion business model & stock analysis

Mabion SA engages in the development and manufacture of biotech drugs. The company is headquartered in Konstantynow Lodzki, Woj. Lodzkie and currently employs 255 full-time employees. The company went IPO on 2010-08-10. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The firm specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. The company focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. The company operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.

Frequently asked questions about Mabion

Analysts currently set an average price target of 10.20 PLN for the Mabion stock (median: 10.20 PLN), implying +25.8 % versus the latest price. The consensus is based on 7 analyst ratings.

7 analysts currently rate the Mabion stock: 0 recommend buying, 2 holding and 5 selling. For 2026, analysts expect Mabion to generate revenue of 28.00 M PLN and earnings per share of -2.00 PLN.

Converted at the current exchange rate, the Mabion share trades at 1.86 EUR (8.11 PLN).

The Mabion share (MAB.WA) is listed on 5 stock exchanges, including: London (0QGW.L), Frankfurt (272.F), München (272.MU).

The expected revenue of Mabion is 28.00 M PLN. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Mabion is -32.32 M PLN. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Mabion is currently -4.06. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Mabion stock.

The price-to-sales ratio (P/S) of Mabion is currently 4.68. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Mabion stock.

The Eulerpool Quality Score for Mabion is 2/10.

The ISIN of Mabion is PLMBION00016. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Mabion is A1J13Q. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Mabion is MAB.WA. The ticker symbol is used to trade Mabion shares on the stock exchange.

Fair ValueTerminal
7.06 PLN
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
61,792.16 PLN
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website mabion.eu
Country
Poland
Currency
PLN
Initial public offering
Aug 10, 2010
ISIN
PLMBION00016
Cusip
X5152W108
Market capitalization
131.06 M PLNMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-4.06
P/Ee 2027
-27.04
P/Ee 2028
—
P/Ee 2029
—
P/Ee 2030
—
P/S
P/Se
4.68
EV/EBIT
—
P/B Ratio
2.68
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-101.78 %
Last updated Oct 22, 2026, 7:50 AM

Mabion Peer Group

Mabion Ticker

FRANKFURT · 272.FLONDON · 0QGW.LMUNICH · 272.MUWARSAW · MAB.WAWSE · MAB.WA

Mabion FIGI

MAB:PW · BBG0014KMQ42MAB15:EO · BBG005FHL910MAB15:XH · BBG005FHL947MAB15:XF · BBG005FHL965MAB15:XE · BBG005FHL983MAB15:XJ · BBG005FHL992MAB15:XL · BBG005FHL9B9MAB15:XG · BBG005FHL9C8MAB15:XO · BBG005FHL9D7MAB15:XP · BBG005FHL9G4MAB15:XS · BBG005FHL9J1MAB15:XA · BBG005FHL9K9

All fundamentals and in-depth analysis of Mabion

Our stock analysis for Mabion stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mabion. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.